New guidance is intended to elicit a stronger immune response and further minimize the risk of rare adverse events The Centers for Disease Control and Prevention (CDC) is providing updates to the Interim Clinical Considerations to elicit a stronger immune response for immunocompromised persons and to further minimize the risk of rare adverse events, specifically myocarditis and pericarditis associated with mRNA COVID-19 vaccines.
Certain immunocompromising conditions prevent an individual from mounting a protective immune response to the primary COVID-19 vaccine series and an additional dose of COVID-19 vaccine is necessary to increase protection against the risk of severe COVID-19 illness, hospitalization and death. After receiving an additional dose of COVID-19 vaccine in the primary series, people who are moderately or severely immunocompromised may need a booster dose sooner than other individuals because protective immunity wanes over time. People who are moderately or severely immunocompromised make up about 3 percent of U.S. adults (at least 10 million people) and include recipients of organ or stem cell transplants, people with advanced or untreated HIV infection, people currently undergoing treatment for cancer, people who are taking certain medications that weaken the immune system, and others. A complete list of conditions can be found on CDC’s website. Full details can be found in the newest technical bulletin on the Division of Public and Behavioral Health web page linked here.
0 Comments
Leave a Reply. |
AuthorThe Bureau of Health Care Quality and Compliance (HCQC) licenses medical and other health facilities, child care facilities and personnel, and medical laboratories and personnel in Nevada. HCQC also conducts compliance surveys and takes complaints. Archives
October 2023
Categories
All
|